Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02545868 · ClinicalTrials.gov registry record · Phase 3
A Study to Evaluate the Effects of Ocrelizumab on Immune Responses In Participants With Relapsing Forms of Multiple Sclerosis
A Phase 3 study, sponsored by Hoffmann-La Roche.
- Completed
- Registry status
- Phase 3
- Development phase
- 102
- Enrollment target
NCT02545868 is a Phase 3 study that has completed, run by Hoffmann-La Roche. The registered enrollment target is 102 participants.
The verdict
NCT02545868, a Phase 3 study, has completed, sponsored by Hoffmann-La Roche.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 102 participants
- Enrollment target
Study Summary
This multicenter, randomized, open-label study will evaluate the immune response to vaccines (tetanus toxoid \[TT\]-containing adsorbed vaccine, 23-valent pneumococcal polysaccharide vaccine \[23-PPV\] either unboosted or boosted with 13-valent pneumococcal conjugate vaccine \[13-PCV\], influenza vaccine, keyhole limpet hemocyanin \[KLH\]) after administration of a dose of ocrelizumab (OCR) in participants with relapsing multiple sclerosis (RMS).
Interventions
- BIOLOGICAL Influenza Vaccine
- BIOLOGICAL KLH
- BIOLOGICAL 23-PPV
- BIOLOGICAL 13-PCV Booster
- DRUG OCR
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 102 participants |
| Start Date | 2015-10-27 |
| Est. Completion | 2021-09-21 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02545868
The ClinicalTrials.gov registry entry for NCT02545868 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 102 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Hoffmann-La Roche, which has 909 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Influenza Vaccine is the first listed.
NCT02545868 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02545868 about?
NCT02545868 is a clinical study titled "A Study to Evaluate the Effects of Ocrelizumab on Immune Responses In Participants With Relapsing Forms of Multiple Sclerosis". This multicenter, randomized, open-label study will evaluate the immune response to vaccines (tetanus toxoid \[TT\]-containing adsorbed vaccine, 23-valent pneumococcal polysaccharide vaccine \[23-PPV\] either unboosted or boosted with 13-valent pneumococcal conjugate vaccine \[13-PCV\], influenza va...
What is the current status of trial NCT02545868?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 102 participants. The study started on 2015-10-27. Estimated completion is 2021-09-21.
What interventions are being tested in trial NCT02545868?
The interventions under investigation include: Influenza Vaccine (BIOLOGICAL), KLH (BIOLOGICAL), 23-PPV (BIOLOGICAL), 13-PCV Booster (BIOLOGICAL), OCR (DRUG).
Who is sponsoring clinical trial NCT02545868?
This trial is sponsored by Hoffmann-La Roche, which has 909 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.